Meeting
2016 Gastrointestinal Cancers Symposium
PET-CT compared to no PET-CT in the management of potentially resectable colorectal cancer liver metastases: The costs implications of a randomized controlled trial.
Authors
Pablo Emilio Serrano Aybar
McMaster University, Hamilton, ON, Canada
Pablo Emilio Serrano Aybar , Amiram Gafni , Chu-Shu Gu , Jim A. Julian , Carol-anne Moulton , Steven Gallinger , Mark Norman Levine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 296)
DOI
10.1200/jco.2016.34.4_suppl.296
Abstract #
296
Poster Bd #
E20
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases. The long-term results of a randomized controlled trial (PET-CT Imaging prior to liver resection for colorectal adenocarcinoma metastases).
First Author: Pablo Emilio Serrano Aybar
Poster
2018 ASCO Annual Meeting
A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastasis.
First Author: Julian Daza Vargas
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prediction of postoperative recurrence by integrating preoperative ctDNA levels and tumor metastasis volume in patients (pts) with colorectal cancer (CRC) with resectable lung or liver metastasis.
First Author: Hidekazu Oyoshi
Poster
2019 ASCO Annual Meeting
Exosomes as novel prognostic biomarker in potentially resectable colorectal cancer liver metastatic (CCLM) patients.
First Author: Ina Valeria Zurlo